5 Key Takeaways
-
1
Systemic complement factors are linked to the progression of intermediate age-related macular degeneration (iAMD) to advanced stages.
-
2
The study tracked 325 iAMD patients over 3.9 years, with 34% progressing to advanced AMD.
-
3
Lower systemic levels of C3 and C5 were associated with increased risk of progression to advanced AMD.
-
4
The classical complement pathway may be a significant driver of iAMD progression and warrants further research.
-
5
Identified biomarkers could aid in risk stratification and the development of targeted therapies for iAMD.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
